Cargando…

Targeting myeloid derived suppressor cells reverts immune suppression and sensitizes BRAF-mutant papillary thyroid cancer to MAPK inhibitors

MAPK signaling inhibitor (MAPKi) therapies show limited efficacy for advanced thyroid cancers despite constitutive activation of the signaling correlates with disease recurrence and persistence. Understanding how BRAF pathway stimulates tumorigenesis could lead to new therapeutic targets. Here, thro...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Peitao, Guan, Haixia, Yuan, Shukai, Cheng, Huili, Zheng, Jian, Zhang, Zhenlei, Liu, Yifan, Yu, Yang, Meng, Zhaowei, Zheng, Xiangqian, Zhao, Li
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8948260/ https://www.ncbi.nlm.nih.gov/pubmed/35332119 http://dx.doi.org/10.1038/s41467-022-29000-5

Ejemplares similares

Author Correction: Targeting myeloid derived suppressor cells reverts immune suppression and sensitizes BRAF-mutant papillary thyroid cancer to MAPK inhibitors
por: Zhang, Peitao, et al.
Publicado: (2022)

BRAF-activated LncRNA functions as a tumor suppressor in papillary thyroid cancer
por: Liao, Tian, et al.
Publicado: (2016)

Hashimoto’s Thyroiditis Minimizes Lymph Node Metastasis in BRAF Mutant Papillary Thyroid Carcinomas
por: Issa, Peter P., et al.
Publicado: (2022)

BRAF in Papillary Thyroid Carcinoma
por: Lanzilotta, Salvatore Giovanni, et al.
Publicado: (2007)

The analysis and validation of the prediction value of conventional and contrast-enhanced ultrasonography for BRAF mutant papillary thyroid microcarcinoma
por: Li, Huilin, et al.
Publicado: (2022)

PAK Signaling Drives Acquired Drug Resistance to MAPK Inhibitors in BRAF-mutant Melanomas
por: Lu, Hezhe, et al.
Publicado: (2017)

BIOL-05. MAPK PATHWAY INHIBITION SENSITIZES TO IMMUNOTHERAPY IN BRAF-MUTANT GLIOMAS
por: Park, Jong-Whi, et al.
Publicado: (2021)

Blood prognostic predictors of treatment response for patients with papillary thyroid cancer
por: Liu, Xiangxiang, et al.
Publicado: (2020)

Paradox breaker BRAF inhibitors have comparable potency and MAPK pathway reactivation to encorafenib in BRAF mutant colorectal cancer
por: Pickles, Oliver J., et al.
Publicado: (2020)

Co-inhibition of SMAD and MAPK signaling enhances (124)I uptake in BRAF-mutant thyroid cancers
por: Luckett, Kathleen A, et al.
Publicado: (2021)

BRAF Testing in Multifocal Papillary Thyroid Carcinoma
por: Kimbrell, Hillary Z., et al.
Publicado: (2015)

zfishbook: connecting you to a world of zebrafish revertible mutants
por: Clark, Karl J., et al.
Publicado: (2012)

BRAF(V600E) status and clinical characteristics in solitary and multiple papillary thyroid carcinoma: experience of 512 cases at a clinical center in China
por: Zheng, Xiangqian, et al.
Publicado: (2012)

miR-22 promotes stem cell traits via activating Wnt/β-catenin signaling in cutaneous squamous cell carcinoma
por: Yuan, Shukai, et al.
Publicado: (2021)

Correction: miR-22 promotes stem cell traits via activating Wnt/β-catenin signaling in cutaneous squamous cell carcinoma
por: Yuan, Shukai, et al.
Publicado: (2022)

STRA6 regulates tumor immune microenvironment and is a prognostic marker in BRAF-mutant papillary thyroid carcinoma
por: He, Weiman, et al.
Publicado: (2023)

Dual Inhibition of MAPK and JAK2/STAT3 Pathways Is Critical for the Treatment of BRAF Mutant Melanoma
por: Zhao, Kun, et al.
Publicado: (2020)

Inhibition of Stearoyl-CoA desaturase 1 reverts BRAF and MEK inhibition-induced selection of cancer stem cells in BRAF-mutated melanoma
por: Pisanu, Maria Elena, et al.
Publicado: (2018)

The Utility of BRAF Testing in the Management of Papillary Thyroid Cancer
por: Melck, Adrienne L., et al.
Publicado: (2010)

Active surveillance as a management strategy for papillary thyroid microcarcinoma
por: Zhang, Huan, et al.
Publicado: (2020)

ERK and p38MAPK combine to improve survival in patients with BRAF mutant colorectal cancer
por: Roseweir, Antonia K., et al.
Publicado: (2018)

Immunological consequences of selective BRAF inhibitors in malignant melanoma: Neutralization of myeloid-derived suppressor cells
por: Schilling, Bastian, et al.
Publicado: (2013)

The Clinicopathological Features of BRAF Mutated Papillary Thyroid Cancers in Chinese Patients
por: Yang, Li-Bo, et al.
Publicado: (2015)

BRAF-activated WT1 contributes to cancer growth and regulates autophagy and apoptosis in papillary thyroid carcinoma
por: Chen, Xing, et al.
Publicado: (2022)

A Suppressor Mutation Partially Reverts the xantha Trait via Lowered Methylation in the Promoter of Genomes Uncoupled 4 in Rice
por: Jiang, Meng, et al.
Publicado: (2019)

Tumorigenesis of Papillary Thyroid Cancer Is Not BRAF-Dependent in Patients with Acromegaly
por: Kim, Hee Kyung, et al.
Publicado: (2014)

Identification of synthetic chemosensitivity genes paired with BRAF for BRAF/MAPK inhibitors
por: Lee, Kye Hwa, et al.
Publicado: (2020)

Silencing FOXP2 reverses vemurafenib resistance in BRAF(V600E) mutant papillary thyroid cancer and melanoma cells
por: Jiang, Suyuan, et al.
Publicado: (2022)

The c-Jun/RHOB/AKT pathway confers resistance of BRAF-mutant melanoma cells to MAPK inhibitors
por: Delmas, Audrey, et al.
Publicado: (2015)

Comment on “ERK and p38MAPK combine to improve survival in patients with BRAF mutant colorectal cancer”
por: Uzunparmak, Burak, et al.
Publicado: (2018)

Prognostic value of the BRAF V600E mutation in papillary thyroid carcinoma
por: HE, GUOPING, et al.
Publicado: (2014)

IL-6 Promotes the Proliferation and Immunosuppressive Function of Myeloid-Derived Suppressor Cells via the MAPK Signaling Pathway in Bladder Cancer
por: Zheng, Zhong, et al.
Publicado: (2021)

A novel tumor suppressor gene NCOA5 is correlated with progression in papillary thyroid carcinoma
por: Zheng, Zhou-Ci, et al.
Publicado: (2018)

MAPK Inhibitors Enhance HDAC Inhibitor-Induced Redifferentiation in Papillary Thyroid Cancer Cells Harboring BRAF(V600E): An In Vitro Study
por: Fu, Hao, et al.
Publicado: (2019)

In Chronic Hepatitis C Infection, Myeloid-Derived Suppressor Cell Accumulation and T Cell Dysfunctions Revert Partially and Late After Successful Direct-Acting Antiviral Treatment
por: Telatin, Valentina, et al.
Publicado: (2019)

Relationship Between Thyroid Autoantibodies and Recurrence of Papillary Thyroid Carcinoma in Children and Adolescents
por: Huang, Dongmei, et al.
Publicado: (2022)

BRAF-mutant hematopoietic malignancies
por: Abdel-Wahab, Omar, et al.
Publicado: (2014)

Genetic analysis of revertants isolated from the rod-fragile fliF mutant of Salmonella
por: Komatsu, Hitomi, et al.
Publicado: (2016)

Comparison of droplet digital PCR and direct Sanger sequencing for the detection of the BRAF (V600E) mutation in papillary thyroid carcinoma
por: Wang, Zhuo, et al.
Publicado: (2019)

Acquired resistance to BRAF inhibition in BRAF(V600E) mutant gliomas
por: Yao, Tsun-Wen, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_rkgqickh83ocn780g2ha5jf8im